CuraGen and TopoTarget Announce Presentation of Belinostat Clinical Trial Results at AACR-NCI-EORTC International ...( - Significant anti-tumor activity of...),Health

- Significant anti-tumor activity of combination IV belinostat in ovarian

cancer reported - - Oral belinostat demonstrated to be safe and well-tolerated in Phase I -

- Presentation of results from two NCI-sponsored clinical trials - - CuraGen to provide a clinical update conference call today at 5:00 p.m.

Eastern Time -

BRANFORD, Conn., Oct. 25 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN), a clinical-stage biopharmaceutical company focused on oncology, and TopoTarget A/S (Copenhagen Stock Exchange: TOPO) announced today that four posters discussing clinical trial results with belinostat were presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, San Francisco, CA. Data reported included Phase II clinical trial results on intravenous belinostat in combination with carboplatin and paclitaxel for relapsed ovarian cancer, Phase I safety and dose-escalation results for oral belinostat, and data from two NCI-sponsored clinical trials including Phase II results evaluating intravenous belinostat monotherapy for the treatment of ovarian cancers and Phase I results of belinostat in combination with bortezomib for advanced tumors.

CLN-8: Phase II Multicenter Trial of Belinostat (PXD101) in Combination with Carboplatin and Paclitaxel (BelCaP) for Patients with Relapsed Ovarian Cancer

Phase II results for CLN-8 were presented by Neil J. Finkler, MD, FACOG, FACS, Investigator and Director of the Gynecologic Oncology Program at Florida Hospital Cancer Institute in Orlando. At the time of the poster presentation, data were available on 23 patients including efficacy data for 16
'/>"/>